UY35918A - Formas cristalinas de un compuesto antiviral - Google Patents

Formas cristalinas de un compuesto antiviral

Info

Publication number
UY35918A
UY35918A UY0001035918A UY35918A UY35918A UY 35918 A UY35918 A UY 35918A UY 0001035918 A UY0001035918 A UY 0001035918A UY 35918 A UY35918 A UY 35918A UY 35918 A UY35918 A UY 35918A
Authority
UY
Uruguay
Prior art keywords
crystal forms
antiviral compound
compound
forms
dioxadiazacycloneonedecino
Prior art date
Application number
UY0001035918A
Other languages
English (en)
Spanish (es)
Inventor
Chan Johann
Bringley Dustin
Fung Peter
Keaton Katie
Lapina Olga
Morrison Henry
Pcion Dominika
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY35918A publication Critical patent/UY35918A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
UY0001035918A 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral UY35918A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
UY35918A true UY35918A (es) 2015-05-29

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035918A UY35918A (es) 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral

Country Status (12)

Country Link
US (2) US9562058B2 (enExample)
EP (1) EP3087086B1 (enExample)
JP (2) JP6568541B2 (enExample)
AR (1) AR098958A1 (enExample)
AU (1) AU2014370124A1 (enExample)
CA (1) CA2934049A1 (enExample)
ES (1) ES2708993T3 (enExample)
NZ (1) NZ720887A (enExample)
PT (1) PT3087086T (enExample)
TW (1) TW201609752A (enExample)
UY (1) UY35918A (enExample)
WO (1) WO2015100144A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440991B2 (en) 2013-12-23 2016-09-13 Gilead Sciences, Inc. Synthesis of an antiviral compound
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
SI2310095T1 (sl) * 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
DK2618831T3 (en) * 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
US20130178413A1 (en) * 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors
UA110354C2 (uk) 2011-11-16 2015-12-25 Гайлід Фармассет Елелсі Противірусні сполуки
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
AU2014370124A1 (en) 2016-06-23
NZ720887A (en) 2018-01-26
EP3087086B1 (en) 2018-11-07
ES2708993T3 (es) 2019-04-12
JP2017503016A (ja) 2017-01-26
WO2015100144A1 (en) 2015-07-02
CA2934049A1 (en) 2015-07-02
AR098958A1 (es) 2016-06-22
EP3087086A1 (en) 2016-11-02
JP2019089819A (ja) 2019-06-13
PT3087086T (pt) 2019-02-06
US20150175625A1 (en) 2015-06-25
US20170267694A1 (en) 2017-09-21
US9562058B2 (en) 2017-02-07
TW201609752A (zh) 2016-03-16
JP6568541B2 (ja) 2019-08-28
US9862728B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
GT201700136A (es) Formas sólidas de un inhibidor ask 1
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201691991A1 (ru) Мультиспецифические антитела
EP3254654A4 (en) Stretch structure for absorbent article, and underpants-type disposable diaper using same
TWD170353S (zh) 項鍊
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
TWD166825S (zh) 飾品
EP3037852A4 (en) Wafer lens, wafer lens array, wafer lens laminate, and wafer lens array laminate
EP3326413A4 (en) USER LEVELS FOR CELLULAR ARCHITECTURE OF THE FIFTH GENERATION
UY35918A (es) Formas cristalinas de un compuesto antiviral
DOP2017000288A (es) Moduladores alostéricos positivos del receptor muscarínico m2.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
EP3279254A4 (en) Polypropylene for film condenser, biaxial stretching film for film condenser, film condenser and manufacturing methods therefor
BR112015026827A2 (pt) Formas polimórficas de cloridrato de nilotinibe
EP3476806A4 (en) SOLUTION, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ACTIVE SUBSTANCE OF SECONDARY BATTERY
EP3242348A4 (en) Method for producing positive active material precursor and positive active material for lithium secondary batteries, exhibiting concentration gradient, and positive active material precursor and positive active material for lithium secondary batteries, exhibiting concentration gradient, produced by same
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP3236520A4 (en) Negative-electrode active material for electrical device, and electrical device using same
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3067969A4 (en) Negative electrode material for secondary battery, and secondary battery using same
EP3067970A4 (en) Negative electrode material for secondary battery, and secondary battery using same
EP2840419A4 (en) SCRAPED LAMINATED BODY, METHOD FOR PRODUCING A THIN POLARIZER, THEREFORE MADE THIN POLARIZER AND POLARIZATION PLATE THEREWITH
EP3064501A4 (en) 2-methylsulphanyl-6-nitro-7-oxo-1, 2, 4-triazolo [5, 1-c][1, 2, 4]triazinide l-arginine dihydrate active toward west nile virus

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230